MIP Discovery, a Bedford, Bedfordshire, UK-based developer of non-biological affinity reagents for cell and gene therapies, raised £7M in Series A funding.
The round was led by Mercia Ventures. Existing investor Calculus Capital also participated along with angel investors.
The company intends to use the funds to drive further commercialisation of its novel synthetic affinity reagents within the cell and gene therapy space, and support recruitment efforts to expand in-house cell and gene therapy expertise.
Led by CEO Stephane Argivier, MIP Discovery designs and develops non-biological affinity reagents to accelerate the development and production of cell and gene therapies. These synthetic antibody alternatives enable insight and control over viral vector characterization and purification, along with contaminant identification and removal.
Commenting on the news, Stephane Argivier said: “Securing funding for a novel reagents company in today’s investment landscape demonstrates clear confidence in MIP Discovery’s technology and renewed commercial strategy. Our proprietary modeling approach to developing synthetic antibody alternatives has already been successful for diagnostic applications, and we have already seen very encouraging traction for our expertise in the cell and gene therapy space.“
FinSMEs
19/02/2024